Category: Partners

DENVER, CO / ACCESS Newswire / June 25, 2025 / ‘Who are you, anyway?’ is the question that opens bestselling author Niccole Hendrickson’s debut book this summer, setting the stage for a transformative and soul-searching journey where she invites women to strip away the roles, rules, and regrets that have kept them small. ST(ripped): A Story of Shedding, Shifting, Shining, and Finding Strength isn’t just a memoir, but a beacon of hope urging you to return to yourself. For every woman ready to shed what no longer serves them, shift into alignment, and shine unapologetically, this is your invitation to rise, reclaim your voice, and write the most powerful story of all: your own.

View Book Trailer Here

In her debut memoir, ST(ripped): A Story of Shedding, Shifting, Shining, and Finding Strength, Niccole unpacks the deeply personal experience of losing everything she once thought defined her, only to discover a more grounded, powerful version of herself rising from within. Niccole’s story is one beyond the superficial celebration of “triumph”, and instead uncovers the beauty that resurfaces beneath the layers of perfectionism, people-pleasing, and societal pressure. When you strip down to only your essence, your true beauty emerges.

“From a young age, I was inspired by those who paved their path…those who chose passion, truth, and unwavering belief in their higher calling,” says Hendrickson. “This book is for the young girls and driven women who know their magic lies within, who are committed to turning inward, shedding what no longer serves them, and rising fully into their power.”

ST(ripped) is more than a memoir: it’s a map created in the wake of personal loss, raw truths, and undeniable growth. Structured in three parts, Niccole takes her readers through her powerful story of shedding old identities, shifting into deeper self-awareness, and shining in her authentic strength. Part One explores Niccole’s roots and the people who shaped her foundation; Part Two journeys into the shadow – the heartbreak, confusion, and surrender that sparked profound personal growth; and Part Three reveals the rise – the alignment of passion and purpose that allows her to live boldly and fully. Throughout, Hendrickson offers readers interactive reflections to inspire their own personal exploration, showing that true strength is found not by proving oneself to the world but by returning home to one’s most authentic self.

Published on June 23rd by Landon Hail Press, ST(ripped) quickly soared to #1 bestseller status in Personal Transformation and Spirituality, Family and Personal Growth, and New Age Self-Help. Photography by Talia Kite.

In ST(ripped), Niccole, a former collegiate athlete, fitness professional, and entrepreneur, fearlessly unpacks her journey of breaking free from perfectionism and people-pleasing, taking readers through the pivotal moments that shaped her. Throughout her story, she explores deep questions of purpose, self-worth, resilience, and intuition. By candidly reflecting on her experiences and rewriting the story of who she thought she had to be, Niccole offers readers a real-life blueprint for stepping into their own power.

The three-part memoir guides readers through Niccole’s personal evolution. From unraveling long-held identities to fully embracing her truest self, her journey reveals the strength that emerges when you dare to live in alignment with your heart and values.

“Niccole consistently inspires women everywhere she goes, and this book gives you a deeper look into how to create confidence and become the person you always dreamt you could be.”

– Juli Bauer Roth, Founder of PaleOMG

Her mission is to inspire women to stand firm in their values, own their purpose, and rise unshaken, knowing that setbacks are never the end but knowing that setbacks are never the end but a stepping stone to becoming more.

“If you’ve ever been foolishly convinced that hiding your greatness behind a shield kept you safe-this book is for you,” says Samantha Joy, Editor-in-Chief at Landon Hail Press. “Niccole helps you vigorously strip away the lies you were taught about who you had to be in order to rediscover the real you. Her prose pulls you into an experience of rebirth, beautifully demonstrating the freedom that lies on the other side of self-abandonment.”

Author Niccole Hendrickson, beautifully photographed by Talia Kite.

As a former collegiate athlete, fitness professional, and entrepreneur, Niccole empowers multifaceted, driven women to channel their grit and ambition, aligning passion with purpose to create unstoppable momentum. She believes setbacks are not the end, but the proving ground, and that legacy is built by turning every challenge into unstoppable growth.

Today, she lives on a 17-acre ranch in the foothills of Colorado with her two kids, two British Labradors, and her husband. You’ll often find her lifting heavy weights, leading with heart at KALO Fitness, journaling at sunrise, building charcuterie boards at sunset, or adventuring across the globe with her family.

This summer, let ST(ripped) be the companion on your own journey of self-return. It’s time to shed. It’s time to shift. It’s time to shine.

“My hope is that ST(ripped) becomes a companion for anyone navigating the beautiful, messy, and transformative journey of resilience – a reminder that your greatest strength is found in the courageous act of becoming,” Hendrickson says.

The stunning cover image for ST(ripped): A Story of Shedding, Shifting, Shining, and Finding Strength, captured by Talia Kite

Dedicated to creating a sacred and transparent space for writers, Landon Hail Press allows authors to own the creative direction of their book and their brand. LHP books have been sold on Amazon, BarnesandNoble.com, Bookshop.org, and more, and featured in major publications like People.com.

Are you an aspiring author? Book a free consultation with Landon Hail Press here.

For further information, please contact: dottie@rebeccacafiero.com

SOURCE: Landon Hail Press

View the original press release on ACCESS Newswire

TAMPA, FL / ACCESS Newswire / June 25, 2025 / Strategos Group is proud to announce the return of former Indiana Superintendent of Public Instruction and former Florida Education Commissioner Dr. Tony Bennett as Partner Emeritus. A nationally recognized leader in education reform, Bennett rejoins the firm he helped shape in its earliest days, bringing decades of experience focused on improving student outcomes.

“Tony’s return to Strategos is both unique and deeply meaningful. In the earliest chapters of our journey, Tony was a foundational force – shaping our mission to advance the American education system,” said Adam Giery, managing partner of Strategos Group. “His return marks a full-circle moment that strengthens our shared commitment to improving the lives of students across the country. Tony joins a remarkable team of former state chiefs, including Johnny Key (Arkansas, 2015-2023), Tom Luna (Idaho, 2006-2014), and Jim Horne (Florida, 2001-2004). His experience, acumen, and perspective will further our portfolio of education enterprises and solidify our position as the nation’s leading education management consultancy.”

Bennett previously served as Indiana Superintendent of Public Instruction and Florida Commissioner of Education, where he led aggressive reform agendas centered on accountability, school choice, and notable student success. Most recently, he served as President of School Management at Stride Learning (K12), a publicly traded company and the nation’s largest provider of virtual K-12 education.

“I’m honored to return to Strategos and rejoin a team deeply committed to advancing the lives of students. I’ve long believed Strategos brings together the sharpest minds and the strongest convictions in the business. This work has always been personal to me – my life’s work has been to elevate outcomes and make a real difference for kids. I’m proud to stand alongside this team once again and contribute to a mission that matters,” Bennett said.

Bennett is widely recognized for leading Indiana through one of the most ambitious education reform efforts in the nation, including the launch of the country’s largest school voucher program, increased Advanced Placement participation, and significant gains on the NAEP and state assessments.

“It’s an honor to welcome Tony, who is one of the most transformative education leaders in the country, back to Strategos. He was instrumental in our early work to shape a firm grounded in integrity, innovation, and student-centered outcomes. Tony brings unmatched insight and a deep understanding of how policy and practice intersect to drive real results. His return strengthens our leadership team and reinforces our unwavering commitment to improving education systems across the country,” said Jim Horne, former Florida education commissioner and a partner at Strategos Group.

About Strategos Group
Founded in 2011, Strategos Group is a national education management consultancy providing expertise to organizations in the education sector. The firm works with Fortune 500 companies, nonprofits, startups, philanthropic organizations, and private equity firms, offering strategic guidance at the national, state, and local levels. Strategos has offices in Arkansas, Florida, Idaho, Indiana, Maryland, Tennessee, Texas, and Washington, D.C.

SOURCE: Strategos Group

View the original press release on ACCESS Newswire

Client-Focused Strategist Elevated to Lead Key Dealership Partnerships

SCOTTSDALE, AZ / ACCESS Newswire / June 25, 2025 / Phone Ninjas, the automotive industry’s leader in dealership-specific coaching and training, proudly announces the promotion of Hannah Mullis to Senior Account Executive. Known for her attention to detail, relationship-building skills, and hands-on approach, Hannah’s promotion reflects her significant impact on dealership performance and her growing role in international client strategy.

“Hannah has become an unbelievable partner to the dealerships she supports,” said Chris Vitale, Chief Operating Officer at Phone Ninjas. “She doesn’t just manage accounts-she makes them better. Her ability to understand what’s really happening in the showroom and offer tailored solutions is what makes her stand out and so effective.”

Since joining Phone Ninjas, Hannah has worked directly with sales, service, and BDC teams, bridging data with real-world coaching to help dealers improve appointment set and show rates, as well as overall customer interactions. In her new role, she’ll take the lead on high-profile accounts, mentor team members, and play a larger part in strategic growth initiatives.

“Our dealers are under enormous pressure,” said Hannah. “They don’t need fluff. They need results: fewer fumbled opportunities, more appointments set, more appointments show, and more sales made. That’s what we’re here for, and I’m excited to keep pushing that mission forward.”

About Phone Ninjas

Founded in 2010, Phone Ninjas helps businesses master all client-facing communications with one goal in mind: better conversations that lead to better results. Through expertly designed ongoing coaching and training programs that support the sales, service, and parts departments, Phone Ninjas helps dealers turn all client interactions into appointments that show and buy – the right way.

Related Video

https://www.youtube.com/watch?v=Apsy2xOi2dc

SOURCE: Phone Ninjas

View the original press release on ACCESS Newswire

KITON Segment Surpasses 1 Million Views as New to The Street Continues to Dominate Financial Media Across Broadcast, Digital, and Outdoor Platforms

NEW YORK CITY, NEW YORK / ACCESS Newswire / June 25, 2025 / New to The Street, one of the most influential financial media platforms in the world, has broken new records with its latest wave of interviews featuring legendary fashion house KITON, financial powerhouse Goldman Sachs (NYSE:GS), automotive icon Ford Motor Company (NYSE:F), and elite sports and education institution IMG Academy, featured through its collaboration with Merrill Lynch, a division of Bank of America (NYSE:BAC).

The segment featuring KITON has officially surpassed 1 million views, making it one of the most impactful interviews in the company’s 16-year broadcast history. These results underscore New to The Street’s expansive influence and trusted position as the go-to media outlet for premium financial storytelling.

“We’re just getting started,” said Vince Caruso, Founder and CEO of New to The Street. “This momentum confirms our platform’s power to spotlight the world’s most recognized brands while elevating emerging leaders. We expect these numbers to grow even faster as we expand into the Middle East and across Asia by year’s end.”

In addition to KITON’s viral performance, the recent Goldman Sachs and Ford interviews have driven strong national viewership, while the IMG Academy / Merrill Lynch profile continues to generate buzz among investors, educators, and sports fans globally.

Each featured interview is supported by New to The Street’s unmatched media ecosystem:

• National TV broadcasts on Bloomberg TV and FOX Business, reaching over 225 million homes weekly

• 2.85 million+ YouTube subscribers with powerful cross-promotion

• 30-day social media campaigns across LinkedIn, X, Instagram, Facebook, and YouTube

• Outdoor dominance with 8-story digital billboards in Times Square and across NYC’s Financial District

• Earned media coverage syndicated to ABC, NBC, and CBS affiliates

With a global audience in over 40 countries, and new offices recently launched in Malaysia and Dubai, New to The Street is poised to become the #1 sponsored and earned financial media platform in the world by 2026.

About New to The Street

New to The Street is one of the longest-running U.S. and international financial media TV brands – broadcasting sponsored content since 2009. Airing weekly on Bloomberg TV and FOX Business, the program features interviews with public and private companies, institutional thought leaders, and market disruptors across a range of industries.

Media Contact:
Monica Brennan
Director of Media Relations
Monica@NewtoTheStreet.com

SOURCE: New To The Street

View the original press release on ACCESS Newswire

June 28 is dedicated to reviewing insurance policies, understanding and learning about coverage options, and ensuring comprehensive protection for individuals and businesses

OVERLAND PARK, KS / ACCESS Newswire / June 25, 2025 / A.D. Banker is proud to champion National Insurance Awareness Day on June 28. Dedicated to education and community engagement, A.D. Banker stresses the importance of being properly insured, encouraging individuals and businesses to review their current policies, explore different coverage types, and confirm they have the right protection in place for life’s unexpected events.

Built on a strong commitment to its core value of making purpose attainable through the right education, A.D. Banker is shining a light on the need for consumer understanding as insurance coverage remains critically low. Currently, too many individuals remain uninsured or underinsured, and don’t realize this until it’s too late. Whether it’s Life & Health, Auto, or Property & Casualty insurance, understanding and securing proper coverage is essential.

“There’s an awareness day for just about everything these days–but this one can truly mean the difference between long-term financial stability or total disaster,” says Pam Reihs, National Insurance Expert for A.D. Banker. “Read your current policies. Make an appointment with your insurance professional. Today’s risks may not be covered by yesterday’s policies. It is worth taking the time to make sure you and your family are protected from life’s ‘what ifs.’”

Beyond increasing personal awareness, this day also serves as an opportunity for insurance agents. A.D. Banker encourages professionals to help fill in this gap of knowledge with their local communities and client base, whether that is on social, in person, or through various local events. Just as valuable is the need for insurance agents to stay compliant and up to date with changing regulations so they can pass along evolving information to their clientele. This type of insider intel can significantly help agents exceed customer expectations and build lasting trust.

For those considering a career in insurance or seasoned professionals looking to expand their knowledge, A.D. Banker offers pre-licensing courses, continuing education programs, and a wealth of study tools. Check out ADBanker.com for more information.

About A.D. Banker
For over 46 years, students have turned to A.D. Banker & Company for the knowledge they need to pass insurance and FINRA licensing exams, and continue their insurance education. The high quality learning design produces outstanding results, and our knowledgeable customer care team provides friendly, responsive support to make the roads to licensing and career advancement easier. Learn more at ADBanker.com. A.D. Banker is part of the Career Certified family of educators. Learn more at CareerCertified.com.

Media Contact:

Career Certified Press
Press@CareerCertified.com
720.822.5314

Contact Information:

Liz Meitus
SVP Corporate Marketing
liz.meitus@careercertified.com
720-822-5314

Buse Kayar
busek@accessnewswire.com

SOURCE: A.D. Banker

View the original press release on ACCESS Newswire

MIAMI, FL / ACCESS Newswire / June 25, 2025 / iTolerance, Inc. (“iTolerance” or the “Company”), an early-stage privately-held biotechnology company focused on the development of innovative regenerative medicines, today announced the appointment of Wayne Pines to the Company’s Board of Directors. Mr. Pines has served as a member of the Company’s Strategic Advisory Board since 2023.

“Wayne has been an integral part of our Strategic Advisory Board and has provided helpful insight as the Company continues to progress our pipeline forward. We are pleased to have him join the Board and believe his expertise will continue to be incredibly important for iTolerance,” said Mitchell Robbins, Chairman of the iTolerance Board of Directors.

“We are thrilled to have Wayne join our Board of Directors. We believe this expansion of our Board is an excellent fit as we transition to a clinical-stage company. As stem cell-derived pancreatic islet products move closer to commercialization, iTOL-100, iTolerance’s immunomodulator, has the potential to remove the need for life-long immunosuppression for these advanced therapies in Type 1 Diabetes. Wayne’s extensive experience with the FDA will help us advance our pipeline and pursue our mission of developing transformative therapies for people living with diabetes and for doctors in search of better treatment options for patients,” commented Anthony Japour, Chief Executive Officer of iTolerance.

Mr. Pines said: “iTolerance’s platform technology using pancreatic islets continues to show promise as a potential treatment option for Type 1 Diabetes by eliminating the need for chronic systemic immunosuppression. This has the potential to be transformational to the Type 1 Diabetes community. I am honored by the opportunity to further support iTolerance as a member of the Board.”

Mr. Pines serves as Senior Director and a member of the International Advisory Council at APCO in Washington, D.C. Mr. Pines is an international consultant on issues related to the Food and Drug Administration (FDA), including media, legislative, regulatory and marketing challenges, and other government agencies. He advises clients on government policies, navigating products through the FDA approval process, and promotional issues.

Mr. Pines served for ten years in senior positions at the FDA, including as Chief of Consumer Education and Information, Chief of Press Relations and Associate Commissioner for Public Affairs. In 2020, he served as a Senior Advisor on COVID-19 to the FDA commissioner. He has authored or edited 16 books about the FDA, including about the product approval process, FDA’s regulation of medical communications, crisis management, and the history of the FDA. His latest book, published in 2022, is “How FDA Really Works: Insights from the Experts.” He is widely published and quoted in the media about the FDA and health care issues and policies. He also is co-host of the podcast FDAWatch (www.fdawatch.net).

Mr. Pines was a Director and former Chairman of the Board of the MedStar Health Research Institute, which oversees research at ten hospitals in the Washington-Baltimore area. He is a Founder, Director and former President of the Alliance for a Stronger FDA, a coalition seeking more appropriated funding for FDA. He was a Co-Founder of the FDA Alumni Association; a member of the Public Health Service’s first Task Force on AIDS Education; Executive Vice President of an international public relations agency; and Chairman of a health care market research firm. He also serves as a member of the Executive Committee of the Regional Board of the Anti-Defamation League.

About iTolerance, Inc.

iTolerance is a regenerative medicine company developing technologies to enable tissue, organoid or cell therapy without requiring life-long immunosuppression. Leveraging its proprietary biotechnology-derived Streptavidin-FasL fusion protein/biotin-PEG microgel (SA-FasL microgel) platform technology, iTOL-100, iTolerance is advancing a pipeline of programs using both allogenic cadaveric and stem cell-derived pancreatic islets to potentially cure Type 1 diabetes. Utilizing iTOL-100 to induce local immune tolerance, the Company is developing its lead indication as a potential cure for Type 1 Diabetes without the need for life-long immunosuppression. Additionally, the Company is developing iTOL-201 for treating liver failure by utilizing hepatocytes and iTOL-401 as a nanoparticle formulation for large organ transplants without the need for life-long immunosuppression. For more information, please visit itolerance.com.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking.

All forward-looking statements are based upon the Company’s current expectations and various assumptions. The Company believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. The Company may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, anticipated levels of revenues, future national or regional economic and competitive conditions, and difficulties in developing the Company’s platform technology. Consequently, forward-looking statements should be regarded solely as the Company’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. The Company cannot guarantee future results, events, levels of activity, performance or achievements. The Company does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Investor Contact
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 908.824.0775
iTolerance@jtcir.com

Media Contact
Susan Roberts
T:202.779.0929
sr@roberts-communications.com

SOURCE: iTolerance, Inc.

View the original press release on ACCESS Newswire

Medical equipment provider delivers on-demand solutions for patients with high BMIs

HOUSTON, TX / ACCESS Newswire / June 25, 2025 / As the nation confronts record-high obesity rates, hospitals are under growing pressure to care for patients with complex, weight-related medical needs. US Med-Equip, a leading provider of rented medical equipment, is helping health systems respond with specialized bariatric equipment and clinical support designed to improve safety, mobility and outcomes for patients with high body mass indexes (BMIs).

More than 42% of U.S. adults are considered obese, according to the Centers for Disease Control and Prevention. Among them, nearly 1 in 10 have a BMI of 40 or higher, qualifying as “severe” or “class III” obesity. These patients often face increased risks for respiratory distress, skin breakdown, and limited mobility. An increasing number of hospitals are responding by turning to US Med-Equip for specialized equipment rentals and support that help them deliver safer, more effective care.

US Med-Equip (USME) is supporting hospitals nationwide with bariatric beds, Advanced WAVE^® therapeutic surfaces, lifts, extra-wide wheelchairs, recliners and other high-capacity equipment built to meet the needs of larger patients.

“Hospitals don’t always know when a patient with bariatric needs will arrive in the ER, but they do know they have to be ready,” said Greg Salario, CEO of US Med-Equip. “We help them respond in those critical moments with equipment that protects both patients and the caregivers at their side.”

Rather than investing in costly equipment that may only be needed intermittently, hospitals are turning to USME to rent bariatric devices and receive 24/7 delivery, setup and support. USME’s clinical teams also provide bedside training and intentional rounding to ensure equipment is properly configured functioning at optimal settings for each patient’s needs.

USME’s bariatric equipment includes:

• Expandable bed frames and therapeutic mattresses with low air loss and pressure redistribution

• Lift and transfer systemsto support safe patient handling and reduce staff injuries

• Reinforced wheelchairs, commodes, and recliners for enhanced comfort and durability

• Respiratory support devices configured for larger patients with compromised breathing

Hospitals count on USME’s teams for critical equipment delivered in two hours plus drive time – faster than anyone else – so their care teams can act without delay when lives are on the line. For more information about US Med-Equip’s bariatric solutions, visit  www.usme.com.

About US Med-Equip:

USME partners with top hospitals to provide the highest quality medical equipment, including monitoring devices, ventilators, infusion pumps, patient beds and more. From on-demand delivery of medical equipment rentals to asset management and onsite biomedical support services, USME is the highest-rated medical equipment partner for hospitals across the country.

Contact Information:

Buse Kayar
busek@accessnewswire.com

SOURCE: US Med-Equip

View the original press release on ACCESS Newswire

New tool lets users instantly compare in-house delivery costs with Dispatch’s on-demand delivery model, driving informed decisions and accelerating business growth.

BLOOMINGTON, MN / ACCESS Newswire / June 25, 2025 / Dispatch, the leading last-mile logistics platform built for businesses of all sizes, announced the launch of its new interactive FleetCost Calculator, a powerful tool designed to help businesses make faster, smarter decisions about their delivery operations and costs.

Built to support business optimization and growth, the Fleet Cost Calculator allows users to instantly compare the costs of maintaining an in-house final-mile delivery fleet with the efficiency and cost-effectiveness of Dispatch’s on-demand delivery model.

This tool puts actionable insights at users’ fingertips, helping them evaluate delivery expenses, reduce overhead, and explore smarter logistics strategies without the guesswork.

“This tool isn’t just a calculator, it’s a conversation starter,” said Alexia Smith, VP of Marketing at Dispatch. “It brings clarity to the often complex cost structures of final-mile delivery, and it makes the case for our model in a way that’s immediate, visual, and grounded in the data. It allows for Dispatch to be more than just a means of delivery; we can help our customers achieve growth goals with a consultative approach.”

Leveraging real data, users will be able to see delivery variables, including the cost per stop, plus monthly and annual costs per vehicle, compared against Dispatch’s fleet for clear savings insights.

Key Features:

• Instant Comparison: Evaluate in-house fleet costs versus Dispatch’s delivery model in seconds.

• Customizable Inputs: Tailor assumptions to reflect the unique delivery profile of each business.

• Strategic Decision-Making: Provides customers with data-driven insights to choose the most cost-effective and scalable delivery approach.

Smarter Fleet Planning Starts Here
Designed with customer empowerment in mind, the Fleet Cost Calculator helps businesses shift from reactive logistics planning to proactive, data-driven decision-making.

Dispatch continues to lead the industry in delivering the tools, transparency, and technology that make enterprise logistics more agile and intelligent.

For more information, visit https://www.dispatchit.com or contact pr@dispatchit.com.

About Dispatch: Dispatch is redefining last-mile delivery for the modern business. As the premier B2B delivery platform, Dispatch empowers organizations with scalable, technology-driven solutions that streamline logistics, enhance visibility, and improve customer satisfaction. Through its robust delivery management software, seamless API integrations, and a reliable network of independent contractor drivers, Dispatch enables businesses of all sizes to simplify and optimize their last-mile operations. Operating in over 80 U.S. markets, Dispatch is trusted by thousands of businesses to deliver what matters-fast, flexibly, and reliably. Learn more at www.dispatchit.com.

###

SOURCE: Dispatch

View the original press release on ACCESS Newswire

Canalevia^® (crofelemer delayed-release tablets), under the name Canalevia-CA1, is conditionally approved by the FDA for treatment of chemotherapy-induced diarrhea in dogs

Jaguar is exploring the possibility of approval of Canalevia for treatment of general diarrhea in dogs in the EU based on the statistically significant data from a completed study

Diarrhea is one of the most common reasons owners bring their dog to the veterinarian and the second most common reason for visits to the veterinary emergency hospital, yet there are currently no FDA-approved drugs to treat general diarrhea in dogs

Company strategy: In discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally

SAN FRANCISCO, CA / ACCESS Newswire / June 25, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), under its Jaguar Animal Health tradename for the veterinary market, today announced that the company plans to pursue approval from the European Medicines Agency’s (EMA) Committee for Veterinary Medicinal Products (CVMP) for Canalevia (crofelemer delayed-release tablets) in the European Union for treatment of general diarrhea in dogs. Canalevia, under the name Canalevia-CA1, is conditionally approved by the U.S. Food and Drug Administration (FDA) as a prescription drug for the treatment of chemotherapy-induced diarrhea (CID) in dogs.

“Jaguar’s primary objective for Canalevia is to identify a partner with which to collaborate to achieve our three parallel goals for the drug: Obtain approval in the EU for Canalevia for treatment of general diarrhea in dogs based on existing Jaguar study data; maintain continuity of availability in the U.S. of Canalevia for treatment of CID in dogs; and to expand the U.S. indication from CID in dogs to treatment of general diarrhea in dogs,” said Lisa Conte, Jaguar’s Founder and CEO. “I’m pleased to report that Jaguar is currently in discussions with multiple potential animal health company partners to collaborate to bring Canalevia to regulatory approval and commercialization for general diarrhea globally.”

Canalevia contains crofelemer, a plant-based botanical prescription drug that modulates chloride channels in the gastrointestinal tract to reduce diarrhea. Importantly, Canalevia is not an antibiotic drug. The overuse and misuse of antibiotics, both in humans and animals, contribute to the development of bacteria that are resistant to antibiotics.

“In the EU, it may be possible to obtain approval of Canalevia for treatment of general diarrhea in dogs based on the results of a study Jaguar completed in 200 dogs with general diarrhea,” Conte said. “While this trial did not meet its stated primary endpoint, the study results are clinically significant when analyzed using an alternate, simplified endpoint, defining treatment success as any dog that had no episodes of diarrhea following the first treatment with either Canalevia or placebo. Using this revised endpoint, the study data shows that dogs treated with Canalevia had significantly better outcomes – with fewer watery stools and significant improvement in fecal scores compared to placebo-treated dogs.”

Jaguar plans to submit a dossier to the European Medicines Agency’s (EMA) Committee for Veterinary Medical Products (CVMP) to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea. If acceptable to the EMA, the company will then submit a Marketing Authorization Application (MAA) for Canalevia for general diarrhea in dogs. If the application is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries.

Data from the European Pet Food Industry Federation concluded that there were 104 million dogs in Europe in 2022. “We’ve been pleased with the marketplace reception of crofelemer for treatment of CID in dogs in the U.S. and believe there is clearly an unmet medical need for a product for the much larger market of treatment of general diarrhea in dogs – both in the U.S. and the EU,” said Conte. “We estimate that U.S. veterinarians see approximately six million annual cases of acute and chronic diarrhea in dogs, and we look forward to identifying a partner to fund and execute development and commercialization of crofelemer for the treatment of general diarrhea in the U.S. and/or globally. Forging a partnership for this purpose is a key focus of our business development efforts in 2025 and has been designated as a key potential catalyst for the company this year.”

Diarrhea is one of the most common reasons dogs are seen by general practice veterinarians and is the second most common reason for visits to veterinary emergency hospitals, yet there is currently no FDA-approved drug to treat general, non-infectious diarrhea in dogs. According to the American Veterinary Medical Association, there were an estimated 89.7 million dogs in the United States in 2024, with nearly half (45.5%) of U.S. households owning a dog in 2024. Devastating diarrhea-related dehydration can occur rapidly for the animal, and the lack of easy access to outdoor facilities is a significant problem for families living in urban settings with dogs.

Canalevia-CA1, a canine-specific formulation of crofelemer, Jaguar’s novel, oral plant-based drug sustainably harvested from the Croton lechleri tree, is available from multiple leading veterinary distributors in the U.S., including Chewy.

About Conditional Approval and Full Approval

Canalevia-CA1 initially received conditional approval in December 2021 from the FDA for the treatment of CID in dogs. FDA’s conditional approval allows a drug company to legally promote, advertise and sell the animal drug for the labeled uses before proving it meets the “substantial evidence” standard of effectiveness for full approval. The conditional approval is valid for one year, with up to four annual renewals, for a total of five years of conditional approval. To receive a renewal from the FDA, the company must show active progress toward proving “substantial evidence of effectiveness” for full approval. After collecting the remaining effectiveness data, the company then applies to the FDA for full approval. The FDA reviews the application and, if appropriate, fully approves the drug.

About Chemotherapy-induced Diarrhea (CID) in Dogs

According to the American Veterinary Medical Association, approximately 1 in 4 dogs will at some stage in their life develop cancer. Nearly half of dogs over 10 will develop cancer.¹ According to the National Cancer Institute at the National Institutes of Health, roughly 6 million new cancer diagnoses are made in dogs yearly in the U.S.

Due to the increasing number of chemotherapeutic agents, chemotherapy is fast becoming the most widely used cancer treatment in veterinary medicine. Studies have found the incidence of CID to be one of the three most prevalent side effects in dogs undergoing cancer treatment,² and managing side-effects such as diarrhea can be important to maintain successful cancer treatment. More than half of the U.S. veterinarians who responded to a Jaguar-sponsored survey reported that CID interferes with their patients’ chemotherapy treatment plans, indicating an unmet need for an effective product for the treatment of CID.

Canalevia-CA1 is a tablet that can be given orally twice a day and can be used for home treatment of CID in dogs.

About Canalevia^®-CA1

Canalevia-CA1 (crofelemer delayed-release tablets) is the first and only oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea (CID) in dogs. Canalevia-CA1 is a canine-specific formulation of crofelemer, an active pharmaceutical ingredient isolated and purified from the Croton lechleri tree. Canalevia-CA1 is currently conditionally approved by the FDA under application number 141-552. Conditional approval allows for commercialization of the product while Jaguar continues to collect the substantial evidence of effectiveness required for full approval. Jaguar has also received Minor Use in a Major Species (MUMS) designation from the FDA for Canalevia-CA1 to treat CID in dogs. FDA has established a “small number” threshold for minor use in each of the seven major species covered by the MUMS act. The small number threshold is currently 80,000 for dogs, representing the largest number of dogs that can be affected by a disease or condition over the course of a year and still have the use qualify as a minor use.

About Crofelemer

Crofelemer is the only oral FDA-approved prescription drug under botanical guidance. It is plant-based, extracted and purified from the red bark sap of the Croton lechleri tree in the Amazon Rainforest. Napo Pharmaceuticals, a Jaguar family company, has established a sustainable harvesting program under fair trade practices, for crofelemer to ensure a high degree of quality, ecological integrity, and support for Indigenous communities.

Important Safety Information About Canalevia^®-CA1

For oral use in dogs only. Not for use in humans. Keep Canalevia-CA1 (crofelemer delayed-release tablets) in a secure location out of reach of children and other animals. Consult a physician in case of accidental ingestion by humans. Do not use in dogs that have a known hypersensitivity to crofelemer. Prior to using Canalevia-CA1, rule out infectious etiologies of diarrhea. Canalevia-CA1 is a conditionally approved drug indicated for the treatment of chemotherapy-induced diarrhea in dogs. The most common adverse reactions included decreased appetite, decreased activity, dehydration, abdominal pain, and vomiting.

Caution: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Use only as directed. It is a violation of Federal law to use this product other than as directed in the labeling. Conditionally approved by FDA pending a full demonstration of effectiveness under application number 141-552.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. (Jaguar) is a commercial stage pharmaceuticals company focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Jaguar family company Napo Pharmaceuticals (Napo) focuses on developing and commercializing human prescription pharmaceuticals for essential supportive care and management of neglected gastrointestinal symptoms across multiple complicated disease states. Jaguar family company Napo Therapeutics is an Italian corporation Jaguar established in Milan, Italy in 2021 focused on expanding crofelemer access in Europe and specifically for orphan diseases. Jaguar Animal Health is a Jaguar tradename. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar’s Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Canalevia-CA1, visit canalevia.com

Visit the Make Cancer Less Shitty patient advocacy program on Bluesky, X, Facebook & Instagram

Forward-Looking Statements

Certain statements in this press release constitute “forward-looking statements.” These include statements regarding Jaguar’s expectation that it will pursue approval from the EMA’s CVMP for Canalevia in the European Union for treatment of general diarrhea in dogs, Jaguar’s expectation that it will identify a partner to fund and execute development and commercialization of crofelemer for the treatment of general, non-infectious diarrhea in dogs in the U.S. and/or globally, Jaguar’s expectation that it may be possible to obtain approval of Canalevia in the EU for treatment of general diarrhea in dogs based on the results of the study Jaguar completed in 200 dogs with general diarrhea, Jaguar’s expectation that it will submit a dossier to the EMA’s CVMP to outline the results of the updated analysis of the company’s completed study of Canalevia in dogs with general diarrhea, Jaguar’s expectation that, if acceptable to the EMA, the company will then submit a MAA for Canalevia for general diarrhea in dogs, and Jaguar’s expectation that, if the MMA is approved, Canalevia will be marketable for treatment of general diarrhea in dogs in all 27 EU member countries. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

¹ “Cancer in Pets.” American Veterinary Medical Association, 2021, https://www.avma.org/resources/pet-owners/petcare/cancer-pets

² Mason SL, Grant IA, Elliott J, Cripps P, Blackwood L. Gastrointestinal toxicity after vincristine or cyclophosphamide administered with or without maropitant in dogs: a prospective randomised controlled study. J Small Anim Pract. 2014;55:391-398

Contact:

hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

Not for distribution to United States newswire services or for dissemination in the United States

TORONTO, ON / ACCESS Newswire / June 25, 2025 / Northern Superior Resources Inc. (“Northern Superior” or the “Company“) (TSXV:SUP)(OTCQB:NSUPF) is pleased to announce that it has closed its previously announced bought deal financing (see press releases dated June 16, 2025) by issuing 6,500,000 common shares of the Company (the “Common Shares“) at a price of $0.77 per Common Share, for gross proceeds of $5,005,000 (the “Offering“).

Cormark Securities Inc. (the “Underwriter“) acted as sole underwriter and bookrunner of the Offering. In connection with the Offering, the Company paid to the Underwriter a cash commission equal to approximately 6.0% of the gross proceeds of the Offering.

The net proceeds from the Offering will be used for working capital and general corporate purposes.

The Offering was made pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions, as amended and supplemented by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “LIFE Exemption“). The securities issued to Canadian resident subscribers pursuant to the LIFE Exemption will not be subject to a hold period pursuant to applicable Canadian securities laws. A copy of the offering document dated June 16, 2025 prepared by the Company in connection with the LIFE Exemption is available electronically under the Company’s issuer profile on SEDAR+ at www.sedarplus.ca and on the Company’s website at www.nsuperior.com. Final acceptance by the TSX Venture Exchange (the “TSX-V“) of the Offering is subject to the completion of customary post-closing filings.

NQ Investissement Minier

The Company is also pleased to announce that NQ Investissement Minier (“NQIM“) has participated in the Offering. NQIM is a Matagami-based regional investment fund dedicated to mining development in Northern Québec. The fund offers financial support and strategic expertise to exploration companies, with investments guided by a sustainable and responsible approach, promoting positive benefits for local and First Nation communities.

This news release does not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of any of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful, including any of the securities in the United States of America. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act“) or any state securities laws and may not be offered or sold within the United States or to, or for account or benefit of, U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration requirements is available. “United States” and “U.S. person” have the meaning ascribed to them in Regulation S under the U.S. Securities Act.

Qualified Person (“QP”)

The technical content and drilling results contained in this news release have been prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101“) and have been reviewed and approved by Ms. Melanie Pichon, P.Geo., Senior Geologist for Northern Superior. Ms. Pichon is a QP under the NI 43-101 and is not considered independent.

About Northern Superior Resources Inc.

Northern Superior is a gold exploration company focused on the Chibougamau Camp in Québec, Canada. The Company has consolidated the largest land package in the region, with total land holdings currently exceeding 62,000 hectares. The main properties include Philibert, Lac Surprise, Chevrier, and Croteau. Northern Superior also owns 56% of ONGold Resources Ltd. (TSXV: ONAU) (OTCQX: ONGRF) which is advancing promising exploration assets in Northern Ontario and Manitoba, including the district scale TPK Project and Monument Bay; Agnico Eagle Mines Limited owns 15% of ONGold Resources Ltd.

The Philibert Project is located 9 km from IAMGOLD Corporation’s Nelligan¹ Gold project. Philibert hosts a maiden 43-101 inferred resource of 48.5 Mt at 1.10 g/t Au for 1,708,800 ounces Au and an indicated resource of 7.9 Mt tonnes at 1.10 g/t Au for 278,900 ounces Au.² Northern Superior holds a majority stake of 75% in the Philibert Project, with the remaining 25% owned by SOQUEM, and retains an option to acquire the full 100% ownership of the project. Chevrier hosts an inferred mineral resource of 15.7 Mt at 1.29 g/t Au for 652,000 ounces Au (underground and open pit) and an indicated mineral resource of 6.4 Mt at 1.26 g/t Au for 260,000 ounces Au.³ Croteau hosts an inferred mineral resource of 11.6 Mt at 1.7 g/t Au for 640,000 ounces Au.⁴ Lac Surprise hosts the Falcon Zone Discovery, interpreted to be the western strike extension of IAMGOLD Corporation’s Nelligan Gold project.

Northern Superior is a reporting issuer in British Columbia, Alberta, Ontario and Québec, and trades on the TSX-V under the symbol SUP and the OTCQB Venture Market under the symbol NSUPF. For further information, please refer to the Company’s website at www.nsuperior.com or the Company’s profile on SEDAR+ at www.sedarplus.ca.

Northern Superior Resources Inc. on Behalf of the Board of Directors

Simon Marcotte, CFA, President and Chief Executive Officer

Contact Information

Katrina Damouni|
Director – Corporate Development
Tel: +44 7795 128583 (Mobile/WhatsApp)
info@nsuperior.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Cautionary Note Regarding Forward-Looking Information

This press release contains forward-looking statements. Forward-looking statements made in this press release include, but are not limited to, the receipt of the TSX-V approval, the use of proceeds of the Offering, the future performance of our business, its operations and its financial performance and condition, as well as management’s objectives, strategies, beliefs and intentions. Forward-looking statements are frequently identified by such words as “may”, “will”, “plan”, “expect”, “anticipate”, “estimate”, “intend” and similar words referring to future events and results. Forward-looking statements are based on the current opinions and expectations of management. All forward-looking information is inherently uncertain and subject to a variety of assumptions, risks and uncertainties, including the speculative nature of mineral exploration and development, fluctuating commodity prices, competitive risks and the availability of financing, as described in more detail in our recent securities filings available at under the Company’s profile on SEDAR+ at www.sedarplus.ca. Actual events or results may differ materially from those projected in the forward-looking statements and we caution against placing undue reliance thereon. We assume no obligation to revise or update these forward-looking statements except as required by applicable law.

View the original press release on ACCESS Newswire